Clinical Report: Association of Cumulative Exposure to TyG-BMI and CVD Risk
Overview
This study investigates the association between cumulative triglyceride-glucose-body mass index (TyG-BMI) exposure and cardiovascular disease (CVD) risk in a Chinese population.
Background
Cardiovascular disease (CVD) remains the leading cause of death globally, necessitating effective risk assessment strategies. Insulin resistance, a key factor in the development of type 2 diabetes, is also recognized as an independent risk factor for CVD. The triglyceride-glucose (TyG) index serves as a practical surrogate marker for insulin resistance, and its combination with body mass index (BMI) into the TyG-BMI index may enhance cardiovascular risk prediction.
Data Highlights
Quartile
Hazard Ratio (95% CI)
Q1
1.00
Q2
1.32 (1.18–1.49)
Q3
1.33 (1.18–1.49)
Q4
1.44 (1.29–1.62)
Key Findings
3,514 incident cardiovascular events occurred during a median follow-up of 10 years.
The risk of CVD increased with higher cumulative TyG-BMI exposure quartiles.
Cox regression analysis showed hazard ratios of 1.32, 1.33, and 1.44 for Q2, Q3, and Q4 compared to Q1.
A significant non-linear relationship was found between cumulative TyG-BMI and CVD risk.
The area under the ROC curve for cumulative TyG-BMI was 0.6047, indicating modestly better performance than TyG and BMI alone.
Clinical Implications
The findings indicate a relationship between cumulative TyG-BMI exposure and CVD risk.
Conclusion
High cumulative TyG-BMI exposure is associated with an increased risk of cardiovascular disease.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.
In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.
